Stock price when the opinion was issued
Provides the key insight into mRNA that underlies the Covid vaccine. The mRNA technology can be developed into therapies that are targeted and safe. They are working on a flu vaccine as well as a cancer vaccine. Their pipeline is vast and the coronavirus vaccine is giving a huge cash hoard to pay for R&D. (Analysts’ price target is $185.00)
This $24 billion German based pharma company has received approvals to continue advancement into a new uterine cancer treatment. It trades at 8x trailing earnings, 1.1x book and supports a 23% ROE. Cash reserves are growing, while stock is bought back. We recommend placing a stop-loss at $78, looking to achieve $137 -- upside potential of 31%. Yield 0%
(Analysts’ price target is $137.07)